|
| 36720090 | Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. | Blood | 2023 |
| 37205201 | CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia. | Front Oncol | 2023 |
| 34316017 | Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. | Leukemia | 2022 |
| 35583300 | Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study. | Leuk Lymphoma | 2022 |
| 35410569 | Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia. | Leuk Lymphoma | 2022 |
| 35834732 | Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia. | Leuk Lymphoma | 2022 |
| 35467243 | Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. | Invest New Drugs | 2022 |
| 35491816 | A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. | Leuk Lymphoma | 2022 |
| 35922444 | Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. | Leukemia | 2022 |
| 33870413 | Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile Neutropenia. | Clin Infect Dis | 2022 |
| 34932793 | Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. | Blood Adv | 2022 |
| 34351368 | Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. | Blood | 2021 |
| 33654204 | Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. | Leukemia | 2021 |
| 32543932 | Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. | Leuk Lymphoma | 2020 |
| 31804723 | Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. | Am J Hematol | 2020 |
| 31980503 | Functional characterization of two rare BCR-FGFR1<sup>+</sup> leukemias. | Cold Spring Harb Mol Case Stud | 2020 |
| 31826241 | Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. | Blood | 2020 |
| 33049054 | Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. | Blood Adv | 2020 |
| 32281456 | Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database. | J Manag Care Spec Pharm | 2020 |
| 32150611 | Single-cell mutational profiling enhances the clinical evaluation of AML MRD. | Blood Adv | 2020 |
| 30673620 | The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). | Leuk Res | 2019 |
| 31695504 | Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study. | Clin Epidemiol | 2019 |
| 30203489 | Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. | Br J Haematol | 2019 |
| 31291378 | Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. | PLoS One | 2019 |
| 31541945 | Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. | Leuk Res | 2019 |
| 31366621 | Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. | Blood | 2019 |
| 31222713 | Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database. | Adv Ther | 2019 |
| 30712406 | Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey. | Curr Med Res Opin | 2019 |
| 30945331 | Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. | Am J Hematol | 2019 |
| 30887583 | Addressing the room for improvement in management of acute promyelocytic leukemia. | Eur J Haematol | 2019 |
| 30760466 | Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. | Blood Adv | 2019 |
| 28744009 | Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. | Leukemia | 2018 |
| 30024784 | CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. | J Clin Oncol | 2018 |
| 30212655 | Chemotherapy based combinations in AML: Time to take a step back? | Leuk Res | 2018 |
| 29802551 | A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. | Int J Hematol | 2018 |
| 30115633 | Non-zero-sum game of transfusions: EOL in leukemia. | Blood | 2018 |
| 30464604 | NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study. | Cancer Manag Res | 2018 |
| 30333627 | Functional genomic landscape of acute myeloid leukaemia. | Nature | 2018 |
| 30466752 | Is there a standard of care for relapsed AML? | Best Pract Res Clin Haematol | 2018 |
| 29504124 | Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study. | Br J Haematol | 2018 |
| 29524739 | Interpretation of clinical endpoints in trials of acute myeloid leukemia. | Leuk Res | 2018 |
| 29695517 | Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study. | Blood | 2018 |
| 29572158 | A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia. | Clin Lymphoma Myeloma Leuk | 2018 |
| 29407182 | Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). | Leuk Res | 2018 |
| 29454474 | Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. | Blood Rev | 2018 |
| 29051022 | Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study. | Biol Blood Marrow Transplant | 2018 |
| 29097499 | Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia. | Haematologica | 2018 |
| 29242304 | Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. | Haematologica | 2018 |
| 27721426 | Isocitrate dehydrogenase mutations in myeloid malignancies. | Leukemia | 2017 |
| 28355571 | Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. | Cell Rep | 2017 |